Nicholas I Paton1, Joseph Musaazi1, Cissy Kityo1, Stephen Walimbwa1, Anne Hoppe1, Apolo Balyegisawa1, Arvind Kaimal1, Grace Mirembe1, Phionah Tukamushabe1, Gilbert Ategeka1, James Hakim1, Henry Mugerwa1, Abraham Siika1, Jesca Asienzo1, Barbara Castelnuovo1, Agnes Kiragga1, Andrew Kambugu1. 1. From the Infectious Diseases Translational Research Programme and Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (N.I.P.); the London School of Hygiene and Tropical Medicine, London (N.I.P.); the Infectious Diseases Institute, Makerere University (J.M., S.W., A.H., A.B., A. Kaimal, J.A., B.C., A. Kiragga, A. Kambugu), the Joint Clinical Research Centre (JCRC) (C.K., H.M.), and the Makerere University Walter Reed Project (G.M.), Kampala, JCRC, Mbarara (P.T.), and JCRC, Fort Portal (G.A.) - all in Uganda; the University of Zimbabwe Clinical Research Centre, Harare (J.H.); and the Moi University School of Medicine, Eldoret, Kenya (A.S.).
Abstract
BACKGROUND: The World Health Organization recommends dolutegravir with two nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human immunodeficiency virus type 1 (HIV-1) infection. Evidence is limited for the efficacy of this regimen when NRTIs are predicted to lack activity because of drug resistance, as well as for the recommended switch of an NRTI from tenofovir to zidovudine. METHODS: In a two-by-two factorial, open-label, noninferiority trial, we randomly assigned patients for whom first-line therapy was failing (HIV-1 viral load, ≥1000 copies per milliliter) to receive dolutegravir or ritonavir-boosted darunavir and to receive tenofovir or zidovudine; all patients received lamivudine. The primary outcome was a week 48 viral load of less than 400 copies per milliliter, assessed with the Food and Drug Administration snapshot algorithm (noninferiority margin for the between-group difference in the percentage of patients with the primary outcome, 12 percentage points). RESULTS: We enrolled 464 patients at seven sub-Saharan African sites. A week 48 viral load of less than 400 copies per milliliter was observed in 90.2% of the patients in the dolutegravir group (212 of 235) and in 91.7% of those in the darunavir group (210 of 229) (difference, -1.5 percentage points; 95% confidence interval [CI], -6.7 to 3.7; P = 0.58; indicating noninferiority of dolutegravir, without superiority) and in 92.3% of the patients in the tenofovir group (215 of 233) and in 89.6% of those in the zidovudine group (207 of 231) (difference, 2.7 percentage points; 95% CI, -2.6 to 7.9; P = 0.32; indicating noninferiority of tenofovir, without superiority). In the subgroup of patients with no NRTIs that were predicted to have activity, a viral load of less than 400 copies per milliliter was observed in more than 90% of the patients in the dolutegravir group and the darunavir group. The incidence of adverse events did not differ substantially between the groups in either factorial comparison. CONCLUSIONS: Dolutegravir in combination with NRTIs was effective in treating patients with HIV-1 infection, including those with extensive NRTI resistance in whom no NRTIs were predicted to have activity. Tenofovir was noninferior to zidovudine as second-line therapy. (Funded by Janssen; NADIA ClinicalTrials.gov number, NCT03988452.).
BACKGROUND: The World Health Organization recommends dolutegravir with two nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human immunodeficiency virus type 1 (HIV-1) infection. Evidence is limited for the efficacy of this regimen when NRTIs are predicted to lack activity because of drug resistance, as well as for the recommended switch of an NRTI from tenofovir to zidovudine. METHODS: In a two-by-two factorial, open-label, noninferiority trial, we randomly assigned patients for whom first-line therapy was failing (HIV-1 viral load, ≥1000 copies per milliliter) to receive dolutegravir or ritonavir-boosted darunavir and to receive tenofovir or zidovudine; all patients received lamivudine. The primary outcome was a week 48 viral load of less than 400 copies per milliliter, assessed with the Food and Drug Administration snapshot algorithm (noninferiority margin for the between-group difference in the percentage of patients with the primary outcome, 12 percentage points). RESULTS: We enrolled 464 patients at seven sub-Saharan African sites. A week 48 viral load of less than 400 copies per milliliter was observed in 90.2% of the patients in the dolutegravir group (212 of 235) and in 91.7% of those in the darunavir group (210 of 229) (difference, -1.5 percentage points; 95% confidence interval [CI], -6.7 to 3.7; P = 0.58; indicating noninferiority of dolutegravir, without superiority) and in 92.3% of the patients in the tenofovir group (215 of 233) and in 89.6% of those in the zidovudine group (207 of 231) (difference, 2.7 percentage points; 95% CI, -2.6 to 7.9; P = 0.32; indicating noninferiority of tenofovir, without superiority). In the subgroup of patients with no NRTIs that were predicted to have activity, a viral load of less than 400 copies per milliliter was observed in more than 90% of the patients in the dolutegravir group and the darunavir group. The incidence of adverse events did not differ substantially between the groups in either factorial comparison. CONCLUSIONS: Dolutegravir in combination with NRTIs was effective in treating patients with HIV-1 infection, including those with extensive NRTI resistance in whom no NRTIs were predicted to have activity. Tenofovir was noninferior to zidovudine as second-line therapy. (Funded by Janssen; NADIA ClinicalTrials.gov number, NCT03988452.).
Authors: Gentille Musengimana; Elysee Tuyishime; Athanase Kiromera; Samuel S Malamba; Augustin Mulindabigwi; Madjid R Habimana; Cyprien Baribwira; Muhayimpundu Ribakare; Savio D Habimana; Josh DeVos; Richard C N Mwesigwa; Eugenie Kayirangwa; Jules M Semuhore; Gallican N Rwibasira; Amitabh B Suthar; Eric Remera Journal: Antivir Ther Date: 2022-06 Impact factor: 1.679
Authors: Kate El Bouzidi; Fati Murtala-Ibrahim; Vivian Kwaghe; Rawlings P Datir; Obinna Ogbanufe; Trevor A Crowell; Man Charurat; Patrick Dakum; Ravindra K Gupta; Nicaise Ndembi; Caroline A Sabin Journal: J Acquir Immune Defic Syndr Date: 2022-05-01 Impact factor: 3.771
Authors: Matthew L Romo; Jessie K Edwards; Aggrey S Semeere; Beverly S Musick; Mark Urassa; Francesca Odhiambo; Lameck Diero; Charles Kasozi; Gad Murenzi; Patricia Lelo; Katarzyna Wyka; Elizabeth A Kelvin; Annette H Sohn; Kara K Wools-Kaloustian; Denis Nash Journal: Clin Infect Dis Date: 2022-09-10 Impact factor: 20.999
Authors: Mark J Siedner; Mahomed-Yunus S Moosa; Suzanne McCluskey; Rebecca F Gilbert; Selvan Pillay; Isaac Aturinda; Kevin Ard; Winnie Muyindike; Nicholas Musinguzi; Godfrey Masette; Melendhran Pillay; Pravikrishnen Moodley; Jaysingh Brijkumar; Tamlyn Rautenberg; Gavin George; Rajesh T Gandhi; Brent A Johnson; Henry Sunpath; Mwebesa B Bwana; Vincent C Marconi Journal: Ann Intern Med Date: 2021-10-26 Impact factor: 51.598
Authors: Samuel Pierre; Iryna Bocharova; Catherine Nguyen; Fabienne Homeus; Gaetane Julmiste; Youry Macius; Vanessa Rouzier; Patrice Severe; Marie Marcelle Deschamps; Colette Guiteau Moise; Clovy Bellot; Johnny Wu; Vanessa R Rivera; Rochelle Sun; Jean W Pape; Bernard Liautaud; Serena P Koenig Journal: Open Forum Infect Dis Date: 2021-11-23 Impact factor: 3.835